旺山旺水-B(02630)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02630 旺山旺水-B

交易中 02-09 10:26:41

110.700

+5.200

+4.93%

最高114.700	最低105.900	成交量8.38万
今开105.900	昨收105.500	日振幅8.34%
总市值185.53亿	流通市值73.81亿	总股本1.68亿
成交额934.97万	换手率0.13%	流通股本6,668万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02630","market":"HK","secType":"STK","nameCN":"旺山旺水-B","latestPrice":110.7,"timestamp":1770603752869,"preClose":105.5,"halted":0,"volume":83800,"delay":0,"changeRate":0.04928909952606638,"floatShares":66677100,"shares":167597800,"eps":-1.452369,"marketStatus":"交易中","change":5.2,"latestTime":"02-09 10:26:41","open":105.9,"high":114.7,"low":105.9,"amount":9349680,"amplitude":0.083412,"askPrice":112,"askSize":1400,"bidPrice":110.7,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-1.545571,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770609600000},"marketStatusCode":2,"adr":0,"listingDate":1762358400000,"exchange":"SEHK","adjPreClose":105.5,"openAndCloseTimeList":[[1770600600000,1770609600000],[1770613200000,1770624000000]],"volumeRatio":5.06741,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02630","defaultTab":"news","newsList":[{"id":"2606714763","title":"港股异动 | 旺山旺水-B(02630)回落近7% 昨日受尼帕疫情催化大涨近11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714763","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606714763?lang=zh_cn&edition=full","pubTime":"2026-01-28 11:04","pubTimestamp":1769569485,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，旺山旺水-B回落近7%，昨日曾大涨近11%。截至发稿，跌6.89%，报101.4港元，成交额1109.93万港元。但值得注意的是，核苷类药物抑制尼帕病毒理论有一定的基础支持，这类病毒其实存在不同毒株，而这类药物对印度本次病毒疫情有多大作用，尚需临床考证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e15c8a706660d4fff69f6a1942e8617d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","02630"],"gpt_icon":0},{"id":"2606917947","title":"武汉病毒研究所，有新发现","url":"https://stock-news.laohu8.com/highlight/detail?id=2606917947","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606917947?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:08","pubTimestamp":1769515722,"startTime":"0","endTime":"0","summary":"图源/央视新闻不过，中国科学院武汉病毒研究所官微披露，肖庚富/张磊砢研究员团队、单超研究员团队联合上海药物研究所、旺山旺水生物医药股份有限公司胡天文博士在国际期刊Emerging Microbes & Infections上发表了题为“The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection”的重要研究成果，证实口服核苷类药物VV116对尼帕病毒具有显著的抗病毒活性，为这一高致死性新发传染病的防治带来新希望。尼帕病毒疫情持续发酵，带动市场对高致病性病毒检测领域的关注，IVD板块情绪升温。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127201438a6b30c9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127201438a6b30c9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","BK1191","BK1583","01877","02630"],"gpt_icon":0},{"id":"1123677388","title":"旺山旺水涨超12%，有研究发现VV116对尼帕病毒有治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1123677388","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123677388?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:23","pubTimestamp":1769484234,"startTime":"0","endTime":"0","summary":"1月27日，$旺山旺水-B$涨超12%，高见112港元创上市新高，有研究发现VV116对尼帕病毒有治疗潜力。该成果首次证实VV116对尼帕病毒的治疗潜力，不仅可作为医护人员、实验室工作者等高危人群的预防性用药，更可为应对当下和未来的尼帕病毒疫情提供了一个现成的药物选择。公开资料显示，旺山旺水成立于2013年，重点布局神经精神、生殖健康和病毒感染三大治疗领域。","market":"hk","thumbnail":"https://static.tigerbbs.com/55450d779a02a0de3b93c078ca510ac6","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/55450d779a02a0de3b93c078ca510ac6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e15c8a706660d4fff69f6a1942e8617d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02630","BK1191"],"gpt_icon":0},{"id":"2606279251","title":"港股旺山旺水-B一度涨超14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606279251","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606279251?lang=zh_cn&edition=full","pubTime":"2026-01-27 11:02","pubTimestamp":1769482945,"startTime":"0","endTime":"0","summary":"旺山旺水-B(02630.HK)一度涨超14%，截至发稿，涨12.02%，报110港元，成交额1292.81万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273631916061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273631916061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02630","BK1191"],"gpt_icon":0},{"id":"2606276068","title":"港股异动 | 旺山旺水-B(02630)一度涨超14%创新高 有研究发现VV116对尼帕病毒有治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2606276068","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606276068?lang=zh_cn&edition=full","pubTime":"2026-01-27 10:43","pubTimestamp":1769481790,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，旺山旺水-B一度涨超14%，高见112.7港元创上市新高。截至发稿，涨12.02%，报110港元，成交额1292.81万港元。该成果首次证实VV116对尼帕病毒的治疗潜力，不仅可作为医护人员、实验室工作者等高危人群的预防性用药，更可为应对当下和未来的尼帕病毒疫情提供了一个现成的药物选择。公开资料显示，旺山旺水成立于2013年，重点布局神经精神、生殖健康和病毒感染三大治疗领域。去年12月，旺山旺水宣布与先声药业签订许可和合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e15c8a706660d4fff69f6a1942e8617d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02630","BK1191"],"gpt_icon":0},{"id":"2604892711","title":"旺山旺水-B01月19日主力净流入100.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2604892711","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604892711?lang=zh_cn&edition=full","pubTime":"2026-01-19 16:15","pubTimestamp":1768810554,"startTime":"0","endTime":"0","summary":"01月19日, 旺山旺水-B股价涨2.44%，报收92.20元，成交金额870.0万元，换手率0.14%，振幅4.67%，量比0.26。旺山旺水-B今日主力资金净流入100.8万元，上一交易日主力净流出0万元。该股近5个交易日上涨10.78%，主力资金累计净流入100.8万元；近20日主力资金累计净流入1017.7万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119162405a72b96f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119162405a72b96f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02630"],"gpt_icon":0},{"id":"2602373568","title":"旺山旺水-B01月09日主力净流入292.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373568","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602373568?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:15","pubTimestamp":1767946531,"startTime":"0","endTime":"0","summary":"01月09日, 旺山旺水-B股价涨1.74%，报收85.00元，成交金额1922.3万元，换手率0.34%，振幅4.25%，量比2.94。旺山旺水-B今日主力资金净流入292.3万元，上一交易日主力净流出0万元。该股近5个交易日上涨1.13%，主力资金累计净流入292.3万元；近20日主力资金累计净流入492.8万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109161753a4af6c5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109161753a4af6c5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02630","BK1191"],"gpt_icon":0},{"id":"1165476322","title":"一周港股牛熊榜 | 东航周涨17%领跑，力勤资源、新华保险强势！曹操出行、商汤深度回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1165476322","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165476322?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:49","pubTimestamp":1766137794,"startTime":"0","endTime":"0","summary":"月内，货邮周转量上升13.30%。据悉，力勤资源是全球领先的镍龙头企业，全面覆盖镍产业链。12月14日，又一利好政策出台。12月9日晚间，中国人寿发布公告称，今年截至11月30日总保费已突破7000亿元。不过，相关公告消息未止曹操出行股价周二续跌。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","01336","03858","02630","00670","02643","02577","00020","06666","02245"],"gpt_icon":1},{"id":"2592967966","title":"旺山旺水-B(02630.HK)午后拉升逾15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592967966","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592967966?lang=zh_cn&edition=full","pubTime":"2025-12-17 13:57","pubTimestamp":1765951026,"startTime":"0","endTime":"0","summary":"每经AI快讯，旺山旺水-B(02630.HK)午后拉升逾15%，截至发稿涨14.81%，报88港元，成交额1333.12万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512173594119736.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512173594119736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02630","BK1191"],"gpt_icon":0},{"id":"2592663449","title":"港股异动 | 旺山旺水-B(02630)午后拉升逾15% 近期与先声药业就VV116新适应症订立许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2592663449","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592663449?lang=zh_cn&edition=full","pubTime":"2025-12-17 13:38","pubTimestamp":1765949937,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，旺山旺水-B午后拉升逾15%，截至发稿，涨14.81%，报88港元，成交额1333.12万港元。消息面上，旺山旺水本月初发布公告，与先声药业就VV116新适应症订立许可协议。旺山旺水与先声药业强强联合，发挥各自研发、生产及商业化的优势，加速VV116的临床开发和商业化进程，以期惠及更多患者。公开资料显示，旺山旺水重点布局神经精神、生殖健康和病毒感染三大治疗领域。目前，旺山旺水的两款核心产品分别是LV232和TPN171。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02630","BK1583","02096"],"gpt_icon":0},{"id":"2592936869","title":"旺山旺水-B12月16日主力净流入432万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592936869","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592936869?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:15","pubTimestamp":1765872958,"startTime":"0","endTime":"0","summary":"12月16日, 旺山旺水-B股价涨2.89%，报收76.65元，成交金额918.3万元，换手率0.18%，振幅7.38%，量比0.76。旺山旺水-B今日主力资金净流入432万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.73%，主力资金累计净流入301.9万元；近20日主力资金累计净流入418.0万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162234a6a8a87e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162234a6a8a87e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02630","BK1191"],"gpt_icon":0},{"id":"2590515437","title":"上市首月的盘面艺术：旺山旺水-B（02630）从“断崖式暴跌”到“V型反转”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515437","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590515437?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:46","pubTimestamp":1765457213,"startTime":"0","endTime":"0","summary":"第一阶段：恐慌性暴跌与流动性危机11月6日至12日，刚刚上市的旺山旺水经历了一场极限压力测试。此区间结束后，完成了旺山旺水股价“灾后重建”中最关键的工程。第四阶段：主升浪后的健康整固与技术确认12月3日至11日，旺山旺水股价在完成凌厉的主升浪突破后，迎来了首个技术性回调与整固阶段。其一，主动性的获利了结与洗盘；其二，高抛低吸，稳固控盘，进一步降低持仓成本，并测试不同价位的市场供求关系。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02630","01981","BK1128","BK1191"],"gpt_icon":0},{"id":"2588190450","title":"先声药业(02096)与旺山旺水(02630)就氢溴酸氘瑞米德韦新适应症订立许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2588190450","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588190450?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:54","pubTimestamp":1764752083,"startTime":"0","endTime":"0","summary":"金吾财讯 | 先声药业(02096)公告公布，于2025年12月3日，集团与旺山旺水(02630)，就氢溴酸氘瑞米德韦新适应症订立许可协议。据该协议，集团将获得氢溴酸氘瑞米德韦在大中华区，于抗呼吸道合胞病毒（“RSV”）感染以及抗人偏肺病毒（HMPV）感染适应症的独家权益。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/NzVmNzI2NGE4ZDk3NWFhOTZkNGE5Nzk4MDcyMTM1NjM3MTc0MDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NzVmNzI2NGE4ZDk3NWFhOTZkNGE5Nzk4MDcyMTM1NjM3MTc0MDU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02630","BK1191","02096"],"gpt_icon":0},{"id":"2588199820","title":"旺山旺水-B(02630)：稳定价格期间结束、并无稳定价格行动及超额配股权失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2588199820","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588199820?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:41","pubTimestamp":1764751289,"startTime":"0","endTime":"0","summary":"智通财经APP讯，旺山旺水-B(02630)发布公告，有关全球发售的稳定价格期间已于2025年12月3日(即递交香港公开发售申请截止日期后第30日)结束。国际发售中概无超额分配H股。稳定价格操作人或代其行事的任何人士于稳定价格期间并无采取任何稳定价格行动。保荐人兼整体协调人(为其本身及代表国际承销商)并无行使超额配股权，且超额配股权已于2025年12月3日失效。因此，概无H股由公司根据超额配股权发行或将予发行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02630","BK1191"],"gpt_icon":0},{"id":"2588198560","title":"旺山旺水-B(02630)与先声药业(02096)就VV116新适应症订立许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2588198560","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588198560?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:32","pubTimestamp":1764750745,"startTime":"0","endTime":"0","summary":"智通财经APP讯，旺山旺水-B 公布，公司与先声药业集团有限公司就VV116新适应症订立许可协议。根据该协议，公司将授予先声药业VV116在大中华区抗呼吸道合胞病毒感染以及抗人偏肺病毒感染适应症的独家许可权益。旺山旺水与先声药业强强联合，发挥各自研发、生产及商业化的优势，加速VV116的临床开发和商业化进程，以期惠及更多患者。临床研究中，VV116总体安全性良好，未发现严重不良事件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02096","BK1191","02630"],"gpt_icon":0},{"id":"2588035387","title":"【新股IPO】11月港股IPO市场复苏势头仍属强劲 惟近半数新股首日破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035387","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588035387?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:35","pubTimestamp":1764664550,"startTime":"0","endTime":"0","summary":"金吾财讯 | 11月港股IPO市场延续强劲复苏态势，本月赛力斯、小马智行等重磅项目密集落地，进一步巩固全年增长格局。截至2024年12月31日止年度及截至2025年5月31日止五个月，来自羊小咩的收入分别占集团总收入约93.2%及98.1%。其公布的一手中签率仅为0.60%，成为11月港股IPO市场中中签难度最高的新股，11月打新热度高涨，投资者扎堆申购却难逃“一签难求”的局面。目前股价维持于70港元水平。","market":"us","thumbnail":"https://static.szfiu.com/news/20220324/YzUxYTE2NDgwOTA4NjcwODA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YzUxYTE2NDgwOTA4NjcwODA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970750","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00881","LU1102505762.USD","BK1520","BK1170","BK1589","SG9999001226.SGD","BK1191","02698","BK4124","BK4609","00800","BK1239","BK1119","02579","BK1104","LU0173614495.USD","01268","00699","BK1229","BK1583","BK1188","HEXmain","BK1116","LU0287142896.SGD","BK6511","5RE.SI","BK1258","02788","02718","BK6092","BK1144","BK1207","BK1109","02630","BK1531","BK1160"],"gpt_icon":1},{"id":"2586248202","title":"旺山旺水-B(02630)建议实施H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248202","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586248202?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:41","pubTimestamp":1764232887,"startTime":"0","endTime":"0","summary":"智通财经APP讯，旺山旺水-B(02630)发布公告，于2025年11月26日，董事会经考虑及批准实施H股全流通的建议，即将本公司10名股东持有的1亿股本公司未上市股份转换为本公司H股(占本公司于本公告日期已发行股份总数约59.7983%)(H股全流通)。待取得所有相关批准(包括向中国证监会备案)并遵守所有适用法律、法规及规则后，1亿股未上市股份将转换为H股，而本公司亦将向联交所申请批准该等H股于联交所主板上市及买卖(转换及上市)。根据本公司的组织章程细则，转换及上市毋须于股东会上获股东批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02630"],"gpt_icon":0},{"id":"2586898062","title":"从峰会到共赢！方舟健客(06086)、旺山旺水-B(02630)深化“AI+慢病管理”领域战略合作，共筑健康产业数智未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2586898062","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586898062?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:02","pubTimestamp":1764122577,"startTime":"0","endTime":"0","summary":"合作伙伴峰会现场，更迎来方舟健客与苏州旺山旺水生物医药股份有限公司战略合作签约的重要时刻。谢方敏强调，作为深耕慢病管理领域多年的企业，方舟健客对“AI+慢病管理”的探索及应用场景研发，始终坚守“解决真问题、带来真改变”的核心逻辑。据介绍，方舟健客在“AI+慢病管理”领域具备大模型技术优势、应用场景研发能力与全链路服务能力，旺山旺水则在生物医药领域拥有深厚的研发与产品管线积淀。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02630","06086","BK1247"],"gpt_icon":0},{"id":"2583573855","title":"旺山旺水-B11月14日主力净流入163.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2583573855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583573855?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:15","pubTimestamp":1763108130,"startTime":"0","endTime":"0","summary":"11月14日, 旺山旺水-B股价涨23.89%，报收68.20元，成交金额3861.1万元，换手率0.88%，振幅29.34%，量比1.16。旺山旺水-B今日主力资金净流入163.8万元，上一交易日主力净流出89.5万元。该股近5个交易日上涨3.63%，主力资金累计净流入104.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入392.1万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114161733950412ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114161733950412ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02630"],"gpt_icon":0},{"id":"1143322445","title":"港股生物医药股持续走强！旺山旺水-B涨近30%，圣诺医药-B涨超18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143322445","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143322445?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:20","pubTimestamp":1763090400,"startTime":"0","endTime":"0","summary":"11月14日，港股$生物(000504)$医药股盘中逆势拉升，$基石药业-B(02616)$涨超11%，$歌礼制药-B(01672)$涨超9%，$圣诺医药-B(02257)$、$来凯医药-B(02105)$涨近7%，$派格生物医药-B(02565)$、$永泰生物-B(06978)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5d27790606b64b3231c65f4df87c0e89","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02630","02257","02616"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vigonvita.cn","stockEarnings":[{"period":"1week","weight":0.0608},{"period":"1month","weight":0.3187},{"period":"3month","weight":0.5961},{"period":"6month","weight":2.1615},{"period":"ytd","weight":0.2889}],"compareEarnings":[{"period":"1week","weight":-0.0302},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.2713},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州旺山旺水生物医药股份有限公司(简称“旺山旺水”)成立于2013年,是一家综合一体化的生物医药公司,致力于发现、开发和商业化创新小分子药物。公司致力于病毒感染、神经精神及生殖健康领域临床需求的满足。公司创始人团队来自中国科学院上海药物研究所,系药物开发领域的著名科学家,拥有逾20年的行业经验。高管团队平均拥有17年行业相关或专业管理经验。公司构建了覆盖“研究-临床开发-制造-商业化”全产业价值链的端到端能力。\n旺山旺水已形成极具竞争力且多元化的创新药产品管线。其中两项处于商业化或接近商业化阶段,四项处于临床阶段,三项处于临床前阶段。\nMindvy(研发代号:VV116)于2021年12月在乌兹别克斯坦获批上市,用于治疗中和重度新冠病毒感染。民得维(研发代号:VV116)于2023年1月获得中国国家药监局附条件批准上市,并于2025年1月由附条件批准转为常规批准,用于轻中度新冠病毒感染的治疗。VV116用于治疗呼吸道合胞病毒(RSV)感染的II期临床试验正在进行中。TPN171于2022年9月在乌兹别克斯坦获批上市,商品名为Onvita,于2025年7月在中国获批上市,商品名为昂伟达,获批适应症均为男性勃起功能障碍(ED)。\n旺山旺水已在江苏省连云港市建立符合GMP标准的商业化生产设施,总建筑面积约51,955平方米,年设计产能为100百万粒胶囊及600百万片片剂。\n旺山旺水拥有81项授权专利,获得国家高新技术企业、国家专精特新“小巨人”企业、江苏省科技型中小企业、江苏省潜在独角兽企业等荣誉。\n旺山旺水将继续秉持创新驱动发展理念,坚持创新,致力于为中国乃至全球所有患者的健康和生活质量的改善而努力。","exchange":"SEHK","name":"旺山旺水-B","nameEN":"VIGONVITA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"旺山旺水-B(02630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供旺山旺水-B(02630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"旺山旺水-B,02630,旺山旺水-B股票,旺山旺水-B股票老虎,旺山旺水-B股票老虎国际,旺山旺水-B行情,旺山旺水-B股票行情,旺山旺水-B股价,旺山旺水-B股市,旺山旺水-B股票价格,旺山旺水-B股票交易,旺山旺水-B股票购买,旺山旺水-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"旺山旺水-B(02630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供旺山旺水-B(02630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}